{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04842201",
      "orgStudyIdInfo": {
        "id": "CM326HV001"
      },
      "organization": {
        "fullName": "Keymed Biosciences Co.Ltd",
        "class": "INDUSTRY"
      },
      "briefTitle": "Single Ascending Dose Study of CM326 in Healthy Volunteers",
      "officialTitle": "A Phase 1, Randomized, Placebo-Controlled, Double-blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CM326 in Adult Healthy Volunteers"
    },
    "statusModule": {
      "statusVerifiedDate": "2021-11",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-04-13",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2021-09-28",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2021-09-28",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2021-04-08",
      "studyFirstSubmitQcDate": "2021-04-08",
      "studyFirstPostDateStruct": {
        "date": "2021-04-13",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-04-11",
      "lastUpdatePostDateStruct": {
        "date": "2022-04-12",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Keymed Biosciences Co.Ltd",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CM326 in healthy volunteers."
    },
    "conditionsModule": {
      "conditions": [
        "Asthma"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 44,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "CM326",
          "type": "EXPERIMENTAL",
          "description": "subcutaneous injection",
          "interventionNames": [
            "Drug: CM326"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "subcutaneous injection",
          "interventionNames": [
            "Drug: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "CM326",
          "description": "subcutaneous injection",
          "armGroupLabels": [
            "CM326"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "subcutaneous injection",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Safety of CM326 by assessing the number and severity of adverse events, including changes in vital signs, physical examination, laboratory safety tests, and ECGs",
          "timeFrame": "Day 1 through Day 85"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Pharmacokinetics (PK) of CM326",
          "description": "Serum concentrations of CM326 over time",
          "timeFrame": "Day 1 through Day 85"
        },
        {
          "measure": "Pharmacodynamics of CM326",
          "description": "Serum total Immunoglobulin E (IgE) and Thymus and activation regulated chemokine (TARC) over time",
          "timeFrame": "Day 1 through Day 85"
        },
        {
          "measure": "Immunogenicity",
          "description": "anti-drug antibody (ADA)",
          "timeFrame": "Day 1 through Day 85"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Healthy adult male participant,18 to 65 years of age, inclusive.\n* Body Mass Index (BMI) 18 to 26 kg/m2, inclusive.\n* History, physical examination, laboratory tests and test related items of inspection were normal or abnormal without clinically insignificant.\n* Males must abstain from sex or use highly effective methods of birth control.\n* Having given written informed consent prior to undertaking any study-related procedure.\n\nKey Exclusion Criteria:\n\n* Positive for HIV, or Hepatitis B, or C.\n* Positive result on urine drug screen.\n* Clinical laboratory abnormalities of clinical significance, or other clinical findings suggest clinically significant following diseases (including, but not limited to the gastrointestinal tract, kidney, liver, nerve, blood, endocrine, cancer, lung, immune, mental or cardiovascular disease).\n* With any condition that inappropriate for entry into this study.",
      "healthyVolunteers": true,
      "sex": "MALE",
      "minimumAge": "18 Years",
      "maximumAge": "65 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Jie Hou",
          "affiliation": "Peking University Care Luzhong Hospital",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "PKUCare Luzhong Hospital",
          "city": "Zibo",
          "state": "Shandong",
          "country": "China",
          "geoPoint": {
            "lat": 36.79056,
            "lon": 118.06333
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "40185989",
          "type": "DERIVED",
          "citation": "Di Y, Yang L, Zhou J, Zhang L, Huang Y, Jia Y, Yan H, Chen L, Hou Q, Chen B, Luo Z, Hou J. Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults. BioDrugs. 2025 May;39(3):487-498. doi: 10.1007/s40259-025-00714-4. Epub 2025 Apr 4."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D001249",
          "term": "Asthma"
        }
      ],
      "ancestors": [
        {
          "id": "D001982",
          "term": "Bronchial Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D008173",
          "term": "Lung Diseases, Obstructive"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}